GigaGen
Company Details
Status: Private
Employees: 11-50
Location:
San Carlos, California, United States
Type:
sample
Technology:
sample
sample
sample
About: GigaGen, a subsidiary of Grifols, is advancing transformative antibody drugs for immune deficiency, infectious diseases and checkpoint resistant cancers by leveraging industry-leading, single-cell technologies.
GigaGen’s novel technology platforms uniquely capture and recreate complete immune repertoires as functional antibody libraries. This approach has enabled the creation of first-in-class recombinant polyclonal antibody therapies for the treatment of infectious diseases.
GigaGen’s lead oncology asset, GIGA-564, is an anti-CTLA-4 monoclonal antibody that has demonstrated improved anti-tumor efficacy in vivo through a unique mechanism of action.
GigaGen is leveraging its proprietary technology platforms for the continued discovery of novel recombinant polyclonal drugs and monoclonal antibodies to treat life-threatening diseases.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
GigaGen | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.